Jason Kirk

PhD
Molecular and Cellular Biology

Specializing In:

Drug Development Prostate Cancer CTCs IMC Single Cell Sequencing

About Jason Kirk

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Affiliate Member
  • Department of Pharmacology & Therapeutics

Background

Education and Training:

  • 2011 - PhD - Vitamin D and Prostate Cancer Development, University at Buffalo - Roswell Park Division, Buffalo NY
  • 2003 -BS - Biochemistry, Daemen College, Amherst NY

Professional Experience:

  • Small Molecule Screening Shared Resource Advisory Board
  • Lecturer in ICS program at Roswell Park

Honors & Awards:

  • Daemen College Natural Sciences Department Outstanding Graduate
  • American Association of University Professors Academic Future Award
  • Pre-Doctoral National Institutes of Health (NIH) T32 Training Grant
  • Department of Defense (DOD) Pre-Doctoral Prostate Cancer Training Award

Research

Research Overview:

My research interest is in understanding the cellular heterogeneity of the prostate gland. Specifically, how the different cells of the prostate interact with each other under both normal and castration conditions. Understanding these complex cellular relationships will help us better understand prostate cancer biology, and ultimately develop better therapeutic options for patients with this disease.

To study prostate cellular relationships I have been utilizing mouse models and single-cell sequencing technologies. Single-cell sequencing allows us to examine each cell type of the gland under various biological conditions. Using this information we hope to understand how cells communicate and survive under normal and castrate conditions. Improved understanding of the castration resistance process will be applied to therapeutic development strategies for prostate cancer patients undergoing androgen deprivation therapy (ADT).

In addition to understanding prostate cell heterogeneity, my focus is also on the development of better clinical tools to assess prostate cancer patient responsiveness to treatment. To this end we have been developing strategies to isolate, enumerate, and phenotypically analyze circulating tumor cells (CTCs) from patients undergoing treatment for prostate cancer. The use of liquid biopsies to analyze a patient's real-time response to therapeutics would have a major impact on clinical care, and it is our goal to make this a reality.


Publications

Zhang D, Hu Q, Liu X, Ji Y, Chao HP, Liu Y, Tracz A, Kirk J, Buonamici S, Zhu P, Wang J, Liu S, Tang DG. (2020) Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nat Commun. Apr 29;11(1):2089.

Zhang D, Shao S, Li X, Kirk JS, TangDG. (2018) Prostate luminal progenitor cells in development and cancer. Trends Cancer. Nov;4(11):769-783.

Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, Mohler JL, Wang J, Zhao R, Kirk J, Chen X, Tang DG. (2018) Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun. Sep 6;9(1):3600.

Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L. (2015) Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget. Feb 20;6(5):3136-46.

Kirk JS, Ajibade AA , Karasik E, Gillard B, Moser MT, Johnson CS, Trump DL, and Foster BA. (2014). Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer. PLoS one. Feb 26;9:e89555